Global News

H3 Biomedicine, Selvita collaborate

Wednesday, September 18, 2013 01:41 PM

H3 Biomedicine, a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have are collaborating to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

AstraZeneca, Daiichi Sankyo launch reflux esophagitis iPhone app

Wednesday, September 18, 2013 01:36 PM

Daiichi Sankyo and AstraZeneca are working to educate the public about reflux esophagitis through a campaign entitled Do you experience heartburn or acid reflux? The awareness building effort seeks to ensure an accurate understanding of the symptoms of reflux esophagitis and how they affect the daily lives of patients. The campaign incorporates a variety of media, featuring TV commercials, an iPhone app and a website to encourage patients to seek the appropriate treatment and take control of their lives.

More... »

Medtronic opens Ireland Innovation Center

Wednesday, September 18, 2013 12:44 PM

Medtronic, a Minneaplis, Minn.-based medical technology provider, has opened a new Customer Innovation Center (CIC) in Galway, Ireland, providing state-of-the-art facilities for physicians and Medtronic engineers to develop new therapies that will improve clinical outcomes, provide economic value and increase access to quality healthcare for patients around the world.

More... »

Boston Scientific opens China Innovation Center

Wednesday, September 18, 2013 11:25 AM

Boston Scientific, a global medical technology company, has opened the China branch of the Boston Scientific Institute for Advancing Science (IAS) as well as its new Innovation Center. Boston Scientific expects to foster local talent while sustainably developing innovative technologies uniquely suited to the China market.

More... »

Cardiome, Tzamal Medical form commercialization agreement

Wednesday, September 18, 2013 10:57 AM

Cardiome Development, a subsidiary of Cardiome Pharma, and Tzamal Medical Group are collaborating to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Tzamal Medical, a private group of companies providing medical devices and equipment for the healthcare industry, has agreed to specific annual commercial goals for Brinavess, which was approved in Europe for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Financial details of the agreement have not been disclosed.

More... »

IRB Services selects Intralinks VIA

Wednesday, September 18, 2013 10:47 AM

IRB Services (Institutional Review Board Services), a global provider of research ethics review and related services for the clinical research and behavioral science industries, has selected Intralinks VIA to support all of its secure beyond the firewall collaboration needs. Intralinks is a global SaaS provider of inter-enterprise content management and collaboration solutions.

More... »

Treato Pharma launches new version of "patient voice" intelligence

Wednesday, September 18, 2013 10:40 AM

Treato, the source of "patient voice" intelligence, has announced the new version of its Treato Pharma platform for pharmaceutical companies and agencies.

More... »

Chiesi to acquire 100% of Cornerstone Therapeutics

Wednesday, September 18, 2013 09:04 AM

European pharma company Chiesi Farmaceutici will acquire 100% of Cornerstone Therapeutics, a North Carolina-based specialty pharmaceutical company commercializing products for the U.S. hospital and adjacent specialty markets.

More... »

Analysis highlights predictive biomarkers discovery for Vectibix

Monday, September 16, 2013 03:11 PM

Amgen has published a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer (mCRC). Published in the New England Journal of Medicine, the analysis found that RAS mutations, beyond the known KRAS exon 2 mutations, predict lack of response to Vectibix in combination with FOLFOX. RAS mutations are mutations occurring in exons 2, 3 and 4 of KRAS and NRAS.

More... »

DKSH, Bayer expand collaboration to Singapore

Monday, September 16, 2013 03:09 PM

DKSH Business Unit Healthcare, a market expansion services provider that partners with healthcare companies seeking to grow their business in Asia, is collaborating with Bayer Thai to provide services for Bayer's products in Singapore.

More... »